45
Participants
Start Date
September 30, 2014
Primary Completion Date
January 19, 2018
Study Completion Date
March 6, 2018
Melphalan
Melphalan will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
Prednisone
Prednisone will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
Cyclophosphamide
Cyclophosphamide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
Dexamethasone
Dexamethasone will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
Ascorbic acid
Vitamin C will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
PLD
Pegylated liposomal doxorubicin will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
Lenalidomide
Lenalidomide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
Pomalidomide
Pomalidomide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
Lewis Hall Singletary Oncology Center, Thomasville
Cancer Specialists of North Florida, Fleming Island
Hattiesburg Clinic Hematology/Oncology, Hattiesburg
Oncology Specialists, SC, Niles
James Berenson, MD, Inc, West Hollywood
California Cancer Associates for Research & Excellence (cCARE), Encinitas
Comprehensive Cancer Center at Desert Regional Medical Center, Palm Springs
Robert A. Moss, MD, FACP, Inc, Fountain Valley
Comprehensive Blood and Cancer Center, Bakersfield
cCARE Fresno, Fresno
John Muir Health Clinical Research Center, Concord
Vista Oncology, Olympia
Lead Sponsor
Collaborators (1)
Takeda
INDUSTRY
Oncotherapeutics
INDUSTRY